If the advantage of pressure on tumor growth is simply due to PD-L1:PD-1checkpoint, we expect that the CAR-T and Pembrolizumab combination would remain reducing the tumors as shown in Fig. 5D. However, in the real tumor microenvironment, long-term pressure could involve additional mechanisms, which could dampen or even remove the effect of Pembrolizumab on shrinking pressured tumors. This evidence concerns the gene CD274 and neoplasm.